看多

Tesaro buy opportunity

83
European launch and approval for additional indications of currently approved drugs will drive further growth. After a long steady decline and a biotech crash, Tesaro is now significantly undervalued.

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。